Thursday, February 2, 2017  |  Volume 9 / Number 3  |  A Production of the BioProcessing Journal
ISBioTech 7th Spring Meeting
Career Development
Disposable Solutions
Disposable Solutions for Biomanufacturing
February 27–March 1, 2017
Munich, Germany
International Serum Industry Association
12th Annual Meeting
May 3–4, 2017
Hong Kong
Bioassays 2017:
Scientific Approaches & Regulatory Strategies
May 8–9, 2017
Silver Spring, Maryland USA
20th Annual Meeting
May 10–13, 2017
Washington, DC USA
25th ESACT Meeting
25th ESACT Meeting
May 14–17, 2017
Lausanne, Switzerland
ISBioTech 5th Fall Meeting
Economize by combining Techno-Blast and BioProcessing Journal advertising into one package.

Request a media kit today!
Suggested Reading
Quality Risk Management (QRM): Part I — Identifying, Evaluating,
and Mitigating Threat Risks to Biopharmaceutical Enterprises
By Mark F. Witcher, PhD, NNE
Products & Services
Assay Platform Drives Discovery of Unique Biological Insights
The IncuCyte® live-cell analysis platform from Essen BioScience provides turnkey solutions, comprised of innovative instrumentation, optimized reagents and consumables, and sophisticated analytical software for real-time quantitative analysis of living cells. Placed directly into a standard incubator, the IncuCyte system automatically collects and analyzes images throughout the course of an experiment while cells remain unperturbed in a physiologically relevant environment.
Multiple T-flasks or up to six 96 or 384-well microtiter plates fit within the system, increasing productivity and allowing different applications and assays to be run simultaneously. More than 2000 images can be collected per hour, converting traditional endpoint assays to a kinetic format for studying movement, migration, apoptosis, and other cell behaviors.

The IncuCyte system consists of an imaging platform that resides in the cell incubator, and a networked external controller that gathers and processes image data, allowing walk-away analysis and remote data connection.

For more information, please visit
IncuCyte® live-cell analysis platform
Chemically-Defined, Animal Component-Free, Cell Culture Medium for T Cells
Irvine Scientific introduces PRIME-XV® T Cell CDM, the first commercially available chemically-defined, animal component-free medium for T cell culture. The new medium has been developed to maximize consistent growth of T cells while maintaining their functionality and therapeutic potential.

PRIME-XV T Cell CDM provides more consistency between lots while reducing the risk of introducing foreign agents or impurities from undefined components, thereby facilitating scale-up to commercial production and the regulatory submission process.
PRIME-XV T Cell CDM is the ideal complement to the BalanCD® HEK293 system. Introduced earlier this year, BalanCD HEK293 is a chemically-defined, animal component-free medium for the production of viral vectors used to genetically modify T cells for gene therapy and immunotherapy. All products are manufactured using stringent raw material qualification and under Current Good Manufacturing Practices (cGMP) for consistency and reliability.

For more information, please visit
First Fully Integrated Upstream Platform

Sartorius Stedim Biotech (SSB) has developed an innovative and fully integrated technology platform to meet the requirements of today’s upstream bioprocessing. It combines a top-performing expression system with outstanding equipment and process control for the rapid development and scale-up of robust, high-titer commercial manufacturing processes.

Biopharmaceutical manufacturers will be able to reach the clinic in 14 months by leveraging this new platform. The royalty-free CHO expression platform of SSB’s subsidiary, Cellca, delivers the titers required to meet cost of goods objectives. Cellca can establish a research cell bank within just 4 months. The automated ambr15 micro bioreactor system is capable of controlling 24 or 48 micro bioreactor experiments. The system accelerates clone selection and scales up readily to BIOSTAT® STR single-use bioreactors, which have been successfully implemented at pilot and GMP production scales. To reduce early-stage development timelines further still, SSB has integrated more than 100 off-the-shelf and pre-qualified assays from BioOutsource into its platform, allowing the rapid testing and analysis of biosimilar products.

For more information, please visit

integrated technology platform
Career Development
Public Workshop
Identification and Characterization of the Infectious Disease Risks of Human Cells, Tissues, and Cellular and Tissue-based Products
February 8–9, 2017
College Park, Maryland USA
BioProcess Cuba
BPJ Publishing
Now Offers Open Access
BioProcessing Journal BioProcessing Journal
Techno-Blast Masthead
iCell® Cardiomyocytes cultured at a low cell density for ten days, which can induce hypertrophic effects, and immunostained for sarcomeric alpha-actinin (clone EA53) in green and all-actin in red.
Courtesy of Cellular Dynamics International, a FUJIFILM company.
Did a colleague forward this to you? Subscribe here. While we'd hate to see you go, you can unsubscribe instantly.